The mean C max was 1.01 IU per milliliter (95% CI, 0.92 to 1.09) with recombinant ADAMTS13 and 0.19 IU per milliliter (95% CI, 0.15 to 0.22) with standard therapy (Table S8); in other words, on ...

Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2024; 390 (18): 1690 DOI: 10.1056/NEJMoa2402567 ...

TAK-755 is a recombinant ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The BLA is supported by data from a randomized, controlled phase 3 study (ClinicalTrials.gov ...

Caption Hepatic platelet accumulation in PA-ILI was confirmed in both patients and mice. Deficiency of ADAMTS13 plays a critical role in platelet accumulation in PA-ILI, suggesting that ADAMTS13 ...

DOI 10.14218/JCTH.2024.00233 Article Title ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury Article Publication Date 22-Dec-2024 ...

Ji, M., et al. (2024) ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury. A Randomized Clinical Trial. Journal of Clinical and Translational Hepatology ...

About Recombinant ADAMTS13 (rADAMTS13) rADAMTS13 is the first and only recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (ADAMTS13) enzyme replacement therapy ...

SHP655 is a recombinant ADAMTS13, a von Willebrand factor-cleaving (VWF) protease. If approved, SHP655 will become the first ever recombinant ADAMTS13 enzyme replacement therapy.

Today, plasma is the primary source of exogenous ADAMTS13 for treatment and prophylaxis in patients with hereditary TTP. Acute episodes can be treated with plasma infusions, with therapeutic ...